RE:RE:RE:ArticleNotably, the reduced projections were on account of Ontario not having completed a reorder, which has since happened, though Stellick expects Ontario to be a significant contributor to revenue and gross profit in 2022, as demand for local supply of COVID-19 testing components is stronger than ever given ongoing supply chain issues. Overall, Stellick believes Microbix is executing on its growth strategy and that its VTM and QAP segments will continue to find demand in a post-pandemic world.
“Although we are more bullish on COVID-19 testing than last quarter due to the emergence of the omicron variant, we also believe MBX will continue growing its non-COVID product sales and creating new offerings as excess molecular testing capacity pivots to new tests over the medium-term,” Stellick said. “We continue to believe COVID-19 is endemic and regardless of vaccine successes, there will be some level of diagnostic testing necessary in perpetuity, particularly given the recent FDA approval of an oral antiviral for high risk COVID-19 patients.
rjc7 wrote: if that's the case she should correct it